Former J&J Senior Scientific Director and immunology expert joins at a pivotal time. Touchlight driving its dbDNA technology towards clinical development in therapeutic and prophylactic vaccines
28 April, 2020
Cambridge, UK, and Brisbane, CA, 21 April 2020 Mogrify Ltd (Mogrify®), a UK company aiming to transform the development of cell therapies by the systematic discovery of novel cell conversions, and Sangamo Therapeutics (Sangamo) (Nasdaq: SGMO), a genomic medicine company, today announced that they have executed a collaboration and exclusive license agreement for Sangamo to develop allogeneic cell therapies from Mogrify’s proprietary induced pluripotent stem cells (iPSCs) and embryonic stem cells (ESCs) and Sangamo’s zinc finger protein (ZFP) gene-engineered chimeric antigen receptor regulatory T cell (CAR-Treg) technology.
22 April, 2020
Construction of the UK’s New Vaccines Centre by Glencar Construction Starts Well Ahead of Schedule as Timelines are Fast Tracked Due to Covid-19
22 April, 2020
Nottingham-based leading independent DMPK provider, XenoGesis, has been awarded the prestigious Queen’s Award for Enterprise, International Trade, in recognition of its outstanding year-on-year export growth.
22 April, 2020
Panthera’s second clinical trial site in the UK, in North Manchester is open for business.As a standalone site ideal for existing or new trials with much lower contamination risk during COVID-19
21 April, 2020
Last week the Government announced the establishment of large scale national COVID-19 hub laboratories across the UK. The initial laboratories have been established in Cheshire, Milton Keynes and Glasgow.
08 April, 2020
6th April 2020, Alderley Park: Catapult Ventures has announced the appointment of Vijay Curthan as Investment Director in its GM & Cheshire Life Sciences Fund. Vijay joins Catapult with a background in healthcare private equity, investment banking and pharma industry corporate strategy
08 April, 2020
New arrayed B cell CRISPR knockout screening service strengthens support for development of therapeutics for diseases involving the immune system. First in the market, this unique service complements the Company’s T cell screening service
07 April, 2020